Early Chronic Kidney Disease Care Programme delays kidney function deterioration in patients with stage I-IIIa chronic kidney disease: an observational cohort study in Taiwan.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
19 01 2021
Historique:
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 15 5 2021
Statut: epublish

Résumé

To investigate the effect of the Early Chronic Kidney Disease (CKD) Care Programme on CKD progression in patients with CKD stage I-IIIa. Observational cohort study. Taipei Medical University Research Database from three affiliated hospitals. Adult non-pregnant patients with CKD stage I-IIIa from Taipei Medical University Research Database between 1 January 2012 and 31 August 2017 were recruited. These patients were divided into Early CKD Care Programme participants (case) and non-participants (control). The models were matched by age, sex, estimated glomerular filtration rate and CKD stage with 1:2 propensity score to reduce bias between two groups. The risks of CKD stage I-IIIa progression to IIIb between Early CKD Care Programme participants and non-participants. Compared with the control group, the case group demonstrated more comorbidities and higher proportions of hypertension, diabetes mellitus, gout, dyslipidaemia, heart disease and cerebrovascular disease, but had lower risk of progression to CKD stage IIIb before and (HR 0.72; 95% CI 0.61 to 0.85) and after (adjusted HR (aHR) 0.67; 95% CI 0.55 to 0.81) adjustments. Moreover, Kaplan-Meier analysis revealed the cumulative incidence of CKD stage IIIb was significantly lower in the case group than in the control group. Finally, the programme was an independent protective factor against progression to stage IIIb, especially in patients with CKD stage IIIa before (HR 0.72; 95% CI 0.61 to 0.85) and after (aHR 0.67; 95% CI 0.55 to 0.81) adjustments. The Early CKD Care Programme is an independent protective factor against progression of early CKD.

Identifiants

pubmed: 33468527
pii: bmjopen-2020-041210
doi: 10.1136/bmjopen-2020-041210
pmc: PMC7817788
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e041210

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

JAMA. 2017 May 9;317(18):1864-1881
pubmed: 28430830
Clin Exp Nephrol. 2019 Feb;23(2):189-198
pubmed: 30069609
Am J Kidney Dis. 2003 Feb;41(2):310-8
pubmed: 12552491
Lancet. 2012 Sep 1;380(9844):807-14
pubmed: 22717317
Curr Diab Rep. 2011 Feb;11(1):47-55
pubmed: 21076895
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
Diabet Med. 2018 Mar;35(3):300-305
pubmed: 29247554
Atherosclerosis. 2013 Nov;231(1):61-8
pubmed: 24125412
Arthritis Res Ther. 2015 Apr 01;17:90
pubmed: 25889144
Am J Physiol Renal Physiol. 2013 Aug 15;305(4):F495-509
pubmed: 23698117
J Pharmacol Exp Ther. 2013 Jan;344(1):2-7
pubmed: 23131595
Am J Med. 2015 Sep;128(9):977-85.e3
pubmed: 25908394
PLoS One. 2016 Mar 21;11(3):e0151422
pubmed: 26999730
Expert Opin Ther Targets. 2017 Oct;21(10):967-976
pubmed: 28829206
J Hypertens. 2015 Sep;33(9):1729-41; discussion 1741
pubmed: 26136207
Kidney Int. 2015 Nov;88(5):950-7
pubmed: 26221752
JAMA. 2011 Apr 20;305(15):1553-9
pubmed: 21482743
Nihon Rinsho. 2008 Sep;66(9):1747-52
pubmed: 18788405
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
Am J Kidney Dis. 2012 Mar;59(3 Suppl 2):S5-15
pubmed: 22339901
Lancet Glob Health. 2017 Jan;5(1):e89-e95
pubmed: 27955792
PLoS One. 2018 Jun 1;13(6):e0198387
pubmed: 29856821
Am J Kidney Dis. 2019 Mar;73(3 Suppl 1):A7-A8
pubmed: 30798791
Cardiovasc Hematol Disord Drug Targets. 2014;14(3):205-11
pubmed: 24720455
J Intern Med. 2010 Nov;268(5):456-67
pubmed: 20809922
Lancet. 2008 Jun 28;371(9631):2173-82
pubmed: 18586172
Am J Kidney Dis. 2019 Jul;74(1):120-131
pubmed: 30898362

Auteurs

Shu-Fen Niu (SF)

Department of Nursing, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Department of Nursing, Fu Jen Catholic University, New Taipei, Taiwan.
College of Nursing, Taipei Medical University, Taipei, Taiwan.

Chung-Kuan Wu (CK)

Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan m008533@ms.skh.org.tw kevinchang@tmu.edu.tw.
School of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.

Nai-Chen Chuang (NC)

Clinical Data Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan.

Ya-Bei Yang (YB)

Division of Cardiovascular Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.

Tzu-Hao Chang (TH)

Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan m008533@ms.skh.org.tw kevinchang@tmu.edu.tw.
Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH